Form 4: Teva CFO Sells Over 55,000 Shares Under Pre-Arranged Trading Plan

Eliyahu Sharon Kalif, Executive Vice President and Chief Financial Officer of Teva Pharmaceutical Industries Ltd., sold 55,775 ordinary shares for approximately $17.08 per share as part of a pre-scheduled Rule 10b5-1 trading plan.

Summary

• Eliyahu Sharon Kalif, Teva's EVP and Chief Financial Officer, disposed of 55,775 ordinary shares.
• The transaction occurred on June 12, 2025, at a weighted average price of $17.0769 per share.
• The shares were sold in multiple transactions ranging from $17.055 to $17.12.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kalif on November 29, 2024.
• Following this transaction, Mr. Kalif beneficially owns 403,288 ordinary shares.
• Ordinary Shares may be represented by American Depositary Shares (ADS), with each ADS currently representing one Ordinary Share.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be seen negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates any negative implications, as it suggests a planned diversification or liquidity event rather than a reaction to new adverse information.

Negatives

• The sale of shares by a senior executive, even if pre-planned, can sometimes be perceived as a lack of confidence by some investors, although this is mitigated by the 10b5-1 plan.

Future Outlook

The document, a Form 4 filing, does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector. Such filings are standard disclosures for executive stock transactions.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of the executive's direct ownership, but given it's a pre-planned transaction, it is unlikely to significantly impact shareholder confidence or the company's strategic direction.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Eliyahu Sharon Kalif, CFO, Insider Trading, Form 4, Stock Sale, Rule 10b5-1 Plan, Ordinary Shares, American Depositary Shares